ImaginAb and ARTMS Announce Strategic Partnership for Innovative Manufacture of 89Zr CD8 ImmunoPET Agent

Los Angeles, USA and Vancouver, Canada, April 7, 2020 – ImaginAb Inc., a leading clinical stage immuno-oncology imaging company, and ARTMS Products Inc., the global leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotopes, today announced they have entered a multi-year non-exclusive partnership to explore a novel radiochemistry manufacture of ImaginAb’s lead asset 89Zr CD8 ImmunoPET.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...